What is Catskill Dermatology?
Established in 1993, Catskill Dermatology has evolved into a cornerstone of dermatological health in the Mid-Hudson Valley. The practice distinguishes itself through a collaborative clinical model, where dermatologists, physician assistants, and registered nurses integrate their expertise to address a wide spectrum of skin conditions. From managing the skin cancer epidemic prevalent in the Catskill Mountains to treating localized dermatological issues such as Lyme disease-related rashes, the firm provides comprehensive care tailored to diverse ethnicities and skin types.
The company's market position is defined by its deep-rooted community presence and its commitment to clinical pathologic correlation. By prioritizing personalized care in a welcoming environment, Catskill Dermatology has successfully bridged the gap between specialized medical intervention and accessible patient services, establishing a reputation for excellence that spans over three decades of continuous operation.
How much funding has Catskill Dermatology raised?
Catskill Dermatology has raised a total of $315K across 2 funding rounds:
Debt
$150K
Debt
$165K
Debt (2020): $150K with participation from PPP
Debt (2021): $165K led by PPP
Key Investors in Catskill Dermatology
PPP
Public-Private Partnership
What's next for Catskill Dermatology?
With the recent influx of capital, Catskill Dermatology is well-positioned to optimize its operational efficiency and expand its clinical capabilities. The strategic focus will likely center on upgrading diagnostic technologies and potentially increasing the capacity of its existing facilities to meet the growing demand for specialized skin care in the region. By reinvesting in its human capital and medical infrastructure, the practice aims to reinforce its status as the premier provider of dermatological services in the Mid-Hudson Valley.
Furthermore, the firm is expected to leverage this financial stability to enhance its outreach programs, particularly regarding skin cancer awareness and preventative education. As the practice matures, the integration of advanced treatment protocols will remain a priority, ensuring that patients continue to receive evidence-based care that addresses both common and complex dermatological concerns.
